Hotbed/Location
Filter News
Found 599,127 articles
-
Calibre Scientific Expands European Presence and Chromatography Offering With AIT France Acquisition
1/25/2021
Calibre Scientific is pleased to announce the acquisition of AIT France, a manufacturer and distributor of innovative consumables for analytical chemistry and chromatography.
-
OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011
1/25/2021
OSE Immunotherapeutics announced it received a milestone payment of €1.3 million from Bpifrance related to the Company’s collaborative program, EFFIMab, focused on evaluating interleukin-7 receptor antagonist OSE-127/S95011, partnered with Servier1.
-
Eurofins Achieved Revenues in Excess of EUR 5.4bn in 2020, After Continued Momentum in December Across Both Its Core Business and COVID-19 Related Activities
1/25/2021
Before the annual meeting of 300 of its Business Unit leaders on 26 January 2021, Eurofins pre-announces some of its 2020 results.
-
Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration
1/25/2021
Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatment
-
Samsung Bioepis Opens the New State-of-the-Art Headquarters to Accommodate Next Stage of Growth and Innovation
1/25/2021
The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-generation biologic medicines
-
NEUVOGEN Appoints Dr. Christian Ottensmeier Head of Scientific Advisory Board
1/25/2021
NEUVOGEN, an immunoncology company, is pleased to appoint Christian Ottensmeier MD, PhD, FRCP Head of our Scientific Advisory Board.
-
HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)
1/24/2021
Assessing the morphological and architectural changes in collagen fibers with the platform could potentially aid TNBC clinical trials in categorizing patients and monitoring therapeutic responses.
-
First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
1/24/2021
Telix Pharmaceuticals Limited announces that the first patients have been dosed in the Phase III ZIRCON1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx in the United States.
-
CPHO Issue Statement Series on COVID-19: Keeping Up COVID-19 Public Health Measures
1/24/2021
Over the last month, the authorization of two COVID-19 vaccines offered many Canadians – myself included – hope that the end of the pandemic is in sight.
-
Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign
1/24/2021
Mirum underscores its commitment to continued understanding of the rare liver disease through research and support of ALGS community.
-
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
1/23/2021
- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials
-
Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis
1/23/2021
First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus
-
Core One Labs Announces Vocan Assembles Equipment to Produce Biosynthesized Psilocybin
1/23/2021
Core One Labs Inc. is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant production of psilocybin.
-
Statement from the Chief Public Health Officer of Canada on January 23, 2021
1/23/2021
As the resurgence of COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.
-
Colchicine reduces the risk of COVID-19-related complicationsPositive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients
1/23/2021
The Montreal Heart Institute announced that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19.
-
Lupus Research Alliance Hails Approval of Aurinia's Lupkynis(TM) (voclosporin)
1/23/2021
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month
-
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
-
A Look at This Week’s Biotech IPOs
1/22/2021
The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look. -
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
-
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.